Kynam Global Healthcare Master Fund, LP 4
Accession 0000919574-23-004866
Filed
Aug 15, 8:00 PM ET
Accepted
Aug 16, 7:11 PM ET
Size
19.9 KB
Accession
0000919574-23-004866
Insider Transaction Report
- Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.80/sh+50,000$290,000→ 5,753,825 total(indirect: See Footnote) - Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.85/sh+100,000$585,000→ 5,853,825 total(indirect: See Footnote) - Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.94/sh+179,000$1,063,260→ 5,703,825 total(indirect: See Footnote) - Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.96/sh+100,000$596,000→ 5,953,825 total(indirect: See Footnote) - Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.96/sh+86,414$515,027→ 5,142,111 total - Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.96/sh+86,414$515,027→ 5,142,111 total(indirect: See Footnote)
- Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.80/sh+50,000$290,000→ 5,753,825 total(indirect: See Footnote) - Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.96/sh+86,414$515,027→ 5,142,111 total - Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.96/sh+86,414$515,027→ 5,142,111 total(indirect: See Footnote) - Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.94/sh+179,000$1,063,260→ 5,703,825 total(indirect: See Footnote) - Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.85/sh+100,000$585,000→ 5,853,825 total(indirect: See Footnote) - Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.96/sh+100,000$596,000→ 5,953,825 total(indirect: See Footnote)
- Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.96/sh+100,000$596,000→ 5,953,825 total(indirect: See Footnote) - Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.96/sh+86,414$515,027→ 5,142,111 total(indirect: See Footnote) - Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.80/sh+50,000$290,000→ 5,753,825 total(indirect: See Footnote) - Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.96/sh+86,414$515,027→ 5,142,111 total - Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.94/sh+179,000$1,063,260→ 5,703,825 total(indirect: See Footnote) - Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.85/sh+100,000$585,000→ 5,853,825 total(indirect: See Footnote)
- Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.96/sh+86,414$515,027→ 5,142,111 total - Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.80/sh+50,000$290,000→ 5,753,825 total(indirect: See Footnote) - Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.94/sh+179,000$1,063,260→ 5,703,825 total(indirect: See Footnote) - Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.85/sh+100,000$585,000→ 5,853,825 total(indirect: See Footnote) - Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.96/sh+100,000$596,000→ 5,953,825 total(indirect: See Footnote) - Purchase
Common Stock, par value $0.0001 per share
2023-08-10$5.96/sh+86,414$515,027→ 5,142,111 total(indirect: See Footnote)
Footnotes (3)
- [F1]The reported securities are owned directly by Kynam Global Healthcare Master Fund, LP (the "Master Fund"), a private investment fund managed by Kynam Capital Management, LP (the "Adviser"), and separately managed account clients of the Adviser and may be deemed to be indirectly beneficially owned by (i) the Adviser, (ii) Kynam Capital Management GP, LLC (the "Adviser GP"), the general partner of the Adviser and (iii) Yue Tang, the managing member of the Adviser GP. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- [F2]The reported securities are directly owned by the Master Fund. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- [F3]The reported securities are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by Kynam Fund GP, LLC, the general partner of the Master Fund. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Documents
Issuer
2seventy bio, Inc.
CIK 0001860782
Related Parties
1- filerCIK 0001990100
Filing Metadata
- Form type
- 4
- Filed
- Aug 15, 8:00 PM ET
- Accepted
- Aug 16, 7:11 PM ET
- Size
- 19.9 KB